Spyre Therapeutics Inc $SYRE

Recent News (13)

• Spyre Therapeutics Announces Grants of Inducement Awards GlobeNewswire · 04 Sep 2026 WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation …
• Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares Investing.com · 04 Sep 2026 Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares
• Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares Investing.com · 04 Sep 2026 Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares
• Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares Investing.com · 04 Sep 2026 Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares
• Spyre Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire · 03 Sep 2026 WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the …
• Why is Spyre Therapeutics stock sliding today? Investing.com · 26 Aug 2026 Why is Spyre Therapeutics stock sliding today?
• Biggest stock movers Wednesday: SYRE, INTU, BHVN and more Seeking Alpha · 26 Aug 2026 Biggest stock movers Wednesday: SYRE, INTU, BHVN and more  Seeking Alpha
• After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO Investing.com · 26 Aug 2026 After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO  Investing.com
• After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO Investing.com · 25 Aug 2026 After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO
• After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO By Investing.com Investing.com Nigeria · 25 Aug 2026 After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO By Investing.com  Investing.com Nigeria
• After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO By Investing.com Investing.com UK · 25 Aug 2026 After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO By Investing.com  Investing.com UK
• Spyre Therapeutics stock tumbles on trial results Investing.com · 25 Aug 2026 Spyre Therapeutics stock tumbles on trial results
• Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 GlobeNewswire · 25 Aug 2026 Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo…